$MEIP
MEI Pharma, Inc.

2024 Q1 Form 10-Q Financial Statement

#000095017024014640 Filed on February 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2022 Q4
Revenue $0.00 $0.00 $32.74M
YoY Change -100.0% -100.0% 79.65%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.609M $8.018M $8.496M
YoY Change -35.82% -5.63% 7.19%
% of Gross Profit
Research & Development $5.220M $3.912M $15.31M
YoY Change -65.44% -74.45% -28.88%
% of Gross Profit
Depreciation & Amortization $86.00K $85.00K $92.00K
YoY Change -11.34% -7.61% 22.67%
% of Gross Profit
Operating Expenses $5.220M $3.912M $15.31M
YoY Change -65.44% -74.45% -28.88%
Operating Profit -$9.829M -$11.93M $8.926M
YoY Change -40.03% -233.65% -179.45%
Interest Expense $706.0K $869.0K $1.331M
YoY Change -26.23% -34.71% -75.66%
% of Operating Profit 14.91%
Other Income/Expense, Net $702.0K $867.0K -$4.000K
YoY Change -17650.0% -21775.0%
Pretax Income -$9.127M -$11.06M $10.25M
YoY Change -40.88% -207.9% -184.35%
Income Tax
% Of Pretax Income
Net Earnings -$9.127M -$11.06M $10.25M
YoY Change -40.88% -207.9% -184.35%
Net Earnings / Revenue 31.32%
Basic Earnings Per Share -$1.37 -$1.66 $0.08
Diluted Earnings Per Share -$1.37 -$1.66 $0.08
COMMON SHARES
Basic Shares Outstanding 6.663M 6.663M 133.3M
Diluted Shares Outstanding 6.663M 6.663M 133.3M

Balance Sheet

Concept 2024 Q1 2023 Q4 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $56.55M $59.48M $124.2M
YoY Change -49.52% -52.1% -33.15%
Cash & Equivalents $2.368M $5.174M $10.92M
Short-Term Investments $54.18M $54.31M $113.3M
Other Short-Term Assets $2.814M $6.692M $3.568M
YoY Change -27.23% 87.56% -26.02%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00 $5.704M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $59.37M $66.17M $133.4M
YoY Change -50.73% -50.41% -33.52%
LONG-TERM ASSETS
Property, Plant & Equipment $1.058M $1.144M $1.456M
YoY Change -22.55% -21.43% 2.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $11.89M $12.37M $14.15M
YoY Change -13.21% -12.63% 61.96%
TOTAL ASSETS
Total Short-Term Assets $59.37M $66.17M $133.4M
Total Long-Term Assets $11.89M $12.37M $14.15M
Total Assets $71.26M $78.54M $147.6M
YoY Change -46.9% -46.79% -29.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.176M $1.378M $4.067M
YoY Change -27.64% -66.12% -34.99%
Accrued Expenses $5.388M $5.645M $14.35M
YoY Change -66.87% -60.65% 46.91%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.616M $8.038M $22.65M
YoY Change -59.29% -64.52% -25.78%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $10.62M $11.01M $76.57M
YoY Change -86.07% -85.62% -32.51%
Total Long-Term Liabilities $10.62M $11.01M $76.57M
YoY Change -86.07% -85.62% -32.51%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.616M $8.038M $22.65M
Total Long-Term Liabilities $10.62M $11.01M $76.57M
Total Liabilities $20.23M $19.05M $99.23M
YoY Change -79.74% -80.8% -24.95%
SHAREHOLDERS EQUITY
Retained Earnings -$369.8M -$360.7M -$380.5M
YoY Change -6.62% -5.2% 10.13%
Common Stock $420.8M $420.2M $428.9M
YoY Change -2.2% -2.04% 1.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $51.03M $59.49M $48.37M
YoY Change
Total Liabilities & Shareholders Equity $71.26M $78.54M $147.6M
YoY Change -46.9% -46.79% -29.53%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2022 Q4
OPERATING ACTIVITIES
Net Income -$9.127M -$11.06M $10.25M
YoY Change -40.88% -207.9% -184.35%
Depreciation, Depletion And Amortization $86.00K $85.00K $92.00K
YoY Change -11.34% -7.61% 22.67%
Cash From Operating Activities -$2.928M -$11.06M -$14.27M
YoY Change -75.86% -22.52% 66.59%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $7.000K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $122.0K $24.52M $10.47M
YoY Change -98.78% 134.18% -124.17%
Cash From Investing Activities $122.0K $24.51M $10.53M
YoY Change -98.78% 132.71% -124.29%
FINANCING ACTIVITIES
Cash Dividend Paid $11.70M
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -11.66M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -2.928M -11.06M -14.27M
Cash From Investing Activities 122.0K 24.51M 10.53M
Cash From Financing Activities 0.000 -11.66M 0.000
Net Change In Cash -2.806M 1.798M -3.736M
YoY Change 33.3% -148.13% 21.69%
FREE CASH FLOW
Cash From Operating Activities -$2.928M -$11.06M -$14.27M
Capital Expenditures $0.00 $7.000K
Free Cash Flow -$2.928M -$11.06M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001262104
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2028-03-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41827
dei Entity Registrant Name
EntityRegistrantName
MEI Pharma, Inc.
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
51-0407811
dei Entity Address Address Line1
EntityAddressAddressLine1
11455 El Camino Real
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 250
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
369-7100
dei Security12b Title
Security12bTitle
Common Stock, $0.00000002 par value
dei Trading Symbol
TradingSymbol
MEIP
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6662857
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5174000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16906000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
54306000
CY2023Q2 us-gaap Short Term Investments
ShortTermInvestments
83787000
CY2023Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
0
CY2023Q2 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
85000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6692000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6750000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
66172000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
107528000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11222000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11972000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1144000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1309000
CY2023Q4 us-gaap Assets
Assets
78538000
CY2023Q2 us-gaap Assets
Assets
120809000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1378000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
6134000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5645000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12461000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2023Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
317000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1015000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1428000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8038000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
20340000
CY2023Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
0
CY2023Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
64545000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11012000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11300000
CY2023Q4 us-gaap Liabilities
Liabilities
19050000
CY2023Q2 us-gaap Liabilities
Liabilities
96185000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
226000000
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
226000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6663000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6663000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6663000
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6663000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
0
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
420174000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
430621000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-360686000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-405997000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
59488000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
24624000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
78538000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
120809000
CY2023Q4 us-gaap Revenues
Revenues
0
CY2022Q4 us-gaap Revenues
Revenues
32735000
us-gaap Revenues
Revenues
65297000
us-gaap Revenues
Revenues
41465000
CY2023Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3912000
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15313000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7397000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34776000
CY2023Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8018000
CY2022Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8496000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14549000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15982000
CY2023Q4 us-gaap Costs And Expenses
CostsAndExpenses
11930000
CY2022Q4 us-gaap Costs And Expenses
CostsAndExpenses
23809000
us-gaap Costs And Expenses
CostsAndExpenses
21946000
us-gaap Costs And Expenses
CostsAndExpenses
50758000
CY2023Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-11930000
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
8926000
us-gaap Operating Income Loss
OperatingIncomeLoss
43351000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9293000
CY2023Q4 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
0
CY2022Q4 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
486000
us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
0
us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
1603000
CY2023Q4 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
869000
CY2022Q4 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
845000
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
1963000
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
1325000
CY2023Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
CY2022Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-6000
CY2023Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
867000
CY2022Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1327000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1960000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2922000
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-11063000
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
10253000
us-gaap Net Income Loss
NetIncomeLoss
45311000
us-gaap Net Income Loss
NetIncomeLoss
-6371000
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.66
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.66
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.54
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.54
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
6.8
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
6.8
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.96
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.96
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6663000
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6663000
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6663000
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6663000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6663000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6663000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6663000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6663000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
24624000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
56374000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
363000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
81361000
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-11063000
CY2023Q4 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.75
CY2023Q4 us-gaap Dividends Cash
DividendsCash
11660000
CY2023Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
850000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
59488000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
52413000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-16624000
CY2022Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-40000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1559000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
37308000
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
10253000
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
813000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
48374000
us-gaap Profit Loss
ProfitLoss
45311000
us-gaap Profit Loss
ProfitLoss
-6371000
us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
0
us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
1603000
us-gaap Share Based Compensation
ShareBasedCompensation
1213000
us-gaap Share Based Compensation
ShareBasedCompensation
2372000
meip Non Cash Lease Expense
NonCashLeaseExpense
750000
meip Non Cash Lease Expense
NonCashLeaseExpense
703000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
172000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
191000
meip Increase Decrease In Unbilled Receivable
IncreaseDecreaseInUnbilledReceivable
-85000
meip Increase Decrease In Unbilled Receivable
IncreaseDecreaseInUnbilledReceivable
-4340000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-58000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-262000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-4756000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-3851000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-6816000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3526000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-64862000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-28002000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-701000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-619000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29546000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29052000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
33938000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
67862000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
63419000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
92118000
meip Proceeds From The Sale Of Property And Equipment
ProceedsFromTheSaleOfPropertyAndEquipment
0
meip Proceeds From The Sale Of Property And Equipment
ProceedsFromTheSaleOfPropertyAndEquipment
13000
us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
7000
us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
29474000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
24269000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
40000
us-gaap Payments Of Dividends
PaymentsOfDividends
11660000
us-gaap Payments Of Dividends
PaymentsOfDividends
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-11660000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-40000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-11732000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-4823000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16906000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15740000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5174000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10917000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4347000
CY2023Q4 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.75
CY2023Q4 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
1100000
CY2023Q4 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.75
CY2023Q4 meip Closing Agreement
ClosingAgreement
2023-11-17
CY2023Q4 us-gaap Payments Of Dividends
PaymentsOfDividends
11700000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-360700000
CY2023Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
59500000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the valuation of share-based awards, the discount rate used in estimating the present value of the right-of-use assets and lease liabilities, clinical trial accruals and the assessment of our ability to fund our operations for at least the next 12 months from the date of issuance of these condensed consolidated financial statements. We base our estimates on historical experience and other market-specific </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each reporting period and updated to reflect current information. As future events and their effects cannot be determined with precision, actual results may materially differ from those estimates or assumptions.</span>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. Deposits in our checking and money market accounts are maintained in federally insured financial institutions and are subject to federally insured limits or limits set by the Securities Investor Protection Corporation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We attempt to minimize credit risk associated with our cash, cash equivalents and short-term investments by periodically evaluating the credit quality of our primary financial institutions. Our investment portfolio is maintained in accordance with our investment policy, which is designed to preserve capital, safeguard funds and limit exposure to risk. While we maintain cash deposits in Federal Deposit Insurance Corporation insured financial institutions in excess of federally insured limits, we do not believe that we are exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. We have not experienced any losses on such accounts.</span>
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
54300000
CY2023Q2 us-gaap Short Term Investments
ShortTermInvestments
83800000
meip Reduction Limit Of Additional Paid In Capital
ReductionLimitOfAdditionalPaidInCapital
0
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2023Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
0
CY2023Q2 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
85000
CY2022Q2 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
10044000
CY2023Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
317000
CY2022Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
30900000
meip Contract With Customer Liability Revenue Recognized Upon Satisfaction Of Performance Obligations
ContractWithCustomerLiabilityRevenueRecognizedUponSatisfactionOfPerformanceObligations
-317000
CY2023 meip Contract With Customer Liability Revenue Recognized Upon Satisfaction Of Performance Obligations
ContractWithCustomerLiabilityRevenueRecognizedUponSatisfactionOfPerformanceObligations
-5411000
us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
0
CY2023 us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
-16565000
meip Contract With Customer Liability Revenue Recognized Performance Obligations No Longer Commence
ContractWithCustomerLiabilityRevenueRecognizedPerformanceObligationsNoLongerCommence
0
CY2023 meip Contract With Customer Liability Revenue Recognized Performance Obligations No Longer Commence
ContractWithCustomerLiabilityRevenueRecognizedPerformanceObligationsNoLongerCommence
-8607000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0
CY2023Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
317000
CY2023Q4 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0
CY2022Q4 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0
CY2023Q4 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1501000
CY2022Q4 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2174000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1501000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2182000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2350000
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2343000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1206000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1034000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1144000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1309000
CY2023Q4 us-gaap Depreciation
Depreciation
85000
CY2022Q4 us-gaap Depreciation
Depreciation
92000
CY2023Q4 meip Accrued Preclinical And Clinical Costs
AccruedPreclinicalAndClinicalCosts
810000
CY2023Q2 meip Accrued Preclinical And Clinical Costs
AccruedPreclinicalAndClinicalCosts
3663000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2236000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7189000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1541000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1423000
CY2023Q4 meip Accrued Reimbursement To Related Party
AccruedReimbursementToRelatedParty
892000
CY2023Q2 meip Accrued Reimbursement To Related Party
AccruedReimbursementToRelatedParty
0
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
166000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
186000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5645000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12461000
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.51
us-gaap Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
6
us-gaap Lessor Operating Lease Option To Extend
LessorOperatingLeaseOptionToExtend
November 2029
CY2023Q4 us-gaap Operating Lease Payments
OperatingLeasePayments
583000
CY2022Q4 us-gaap Operating Lease Payments
OperatingLeasePayments
567000
us-gaap Operating Lease Payments
OperatingLeasePayments
1167000
us-gaap Operating Lease Payments
OperatingLeasePayments
1133000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1167000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1913000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2477000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2551000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2715000
CY2023Q4 meip Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
4385000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
15208000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3181000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
12027000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1015000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11012000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
12027000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y10M24D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.075
CY2022Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
0
CY2022Q4 meip Number Of Warrants Exercised
NumberOfWarrantsExercised
0
meip Number Of Warrants Exercised
NumberOfWarrantsExercised
0
CY2023Q4 meip Number Of Warrants Exercised
NumberOfWarrantsExercised
0
meip Number Of Warrants Exercised
NumberOfWarrantsExercised
0
CY2023Q4 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
226100000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
226000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
us-gaap Common Stock Voting Rights
CommonStockVotingRights
one vote per share
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 meip Adopted Agreement
AdoptedAgreement
2023-10-01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2023Q4 us-gaap Share Based Compensation
ShareBasedCompensation
850000
CY2022Q4 us-gaap Share Based Compensation
ShareBasedCompensation
813000
us-gaap Share Based Compensation
ShareBasedCompensation
1213000
us-gaap Share Based Compensation
ShareBasedCompensation
2372000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1284907000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
38.32
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
260437000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.9
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
147596000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
38.32
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1397748000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
32.47
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
812884000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
47.01
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y2M12D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2300000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y6M25D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.045
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.029
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y8M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.90
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.841
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.18
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.8

Files In Submission

Name View Source Status
0000950170-24-014640-index-headers.html Edgar Link pending
0000950170-24-014640-index.html Edgar Link pending
0000950170-24-014640.txt Edgar Link pending
0000950170-24-014640-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img104086284_0.jpg Edgar Link pending
img104086284_1.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
img104086284_2.jpg Edgar Link pending
img267926920_0.jpg Edgar Link pending
meip-20231231.htm Edgar Link pending
meip-20231231.xsd Edgar Link pending
meip-ex10_4.htm Edgar Link pending
meip-ex31_1.htm Edgar Link pending
meip-ex31_2.htm Edgar Link pending
meip-ex32_1.htm Edgar Link pending
meip-ex3_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
meip-20231231_htm.xml Edgar Link completed